These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice. Pérez P; Q Marín M; Lázaro-Frías A; Jiménez de Oya N; Blázquez AB; Escribano-Romero E; S Sorzano CÓ; Ortego J; Saiz JC; Esteban M; Martín-Acebes MA; García-Arriaza J Sci Rep; 2018 Nov; 8(1):17385. PubMed ID: 30478418 [TBL] [Abstract][Full Text] [Related]
11. Human Schwann cells are susceptible to infection with Zika and yellow fever viruses, but not dengue virus. Dhiman G; Abraham R; Griffin DE Sci Rep; 2019 Jul; 9(1):9951. PubMed ID: 31289325 [TBL] [Abstract][Full Text] [Related]
12. Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge. Thompson D; Guenther B; Manayani D; Mendy J; Smith J; Espinosa DA; Harris E; Alexander J; Vang L; Morello CS PLoS Negl Trop Dis; 2022 Jul; 16(7):e0010588. PubMed ID: 35793354 [TBL] [Abstract][Full Text] [Related]
13. Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus. Garg H; Mehmetoglu-Gurbuz T; Joshi A Sci Rep; 2020 Mar; 10(1):4017. PubMed ID: 32132648 [TBL] [Abstract][Full Text] [Related]
14. Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated Vaccine. Lima NS; Moon D; Darko S; De La Barrera RA; Lin L; Koren MA; Jarman RG; Eckels KH; Thomas SJ; Michael NL; Modjarrad K; Douek DC; Trautmann L Front Immunol; 2021; 12():640190. PubMed ID: 33717194 [TBL] [Abstract][Full Text] [Related]
15. Zika virus-like particle (VLP) based vaccine. Boigard H; Alimova A; Martin GR; Katz A; Gottlieb P; Galarza JM PLoS Negl Trop Dis; 2017 May; 11(5):e0005608. PubMed ID: 28481898 [TBL] [Abstract][Full Text] [Related]
16. Mapping the diverse structural landscape of the flavivirus antibody repertoire. Sevvana M; Kuhn RJ Curr Opin Virol; 2020 Dec; 45():51-64. PubMed ID: 32801077 [TBL] [Abstract][Full Text] [Related]
18. Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine. Li Y; Merbah M; Wollen-Roberts S; Beckman B; Mdluli T; Curtis DJ; Currier JR; Mendez-Rivera L; Dussupt V; Krebs SJ; De La Barrera R; Michael NL; Paquin-Proulx D; Eller MA; Koren MA; Modjarrad K; Rolland M EBioMedicine; 2023 Nov; 97():104815. PubMed ID: 37793212 [TBL] [Abstract][Full Text] [Related]
19. Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge. Espinosa D; Mendy J; Manayani D; Vang L; Wang C; Richard T; Guenther B; Aruri J; Avanzini J; Garduno F; Farness P; Gurwith M; Smith J; Harris E; Alexander J EBioMedicine; 2018 Jan; 27():61-70. PubMed ID: 29269041 [TBL] [Abstract][Full Text] [Related]
20. Process intensification of EB66® cell cultivations leads to high-yield yellow fever and Zika virus production. Nikolay A; Léon A; Schwamborn K; Genzel Y; Reichl U Appl Microbiol Biotechnol; 2018 Oct; 102(20):8725-8737. PubMed ID: 30091043 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]